Tempus, Inc. is a company.
Key people at Tempus, Inc..
Tempus, Inc. was founded by Eric Lefkofsky (Co-founder and CEO).
Tempus, Inc. was founded by Eric Lefkofsky (Co-founder and CEO).
Key people at Tempus, Inc..
Tempus, Inc. (NASDAQ: TEM) is a technology company advancing precision medicine through AI-powered platforms that analyze vast multimodal health data, including clinical, molecular, and imaging information. It builds an "operating system" for precision medicine, offering Intelligent Diagnostics, genomic profiling, and data services that serve physicians, patients, and biopharma companies to personalize treatments, match clinical trials, and accelerate drug discovery.[1][2][3][5]
Initially focused on oncology, Tempus has expanded to cardiology, psychiatry (e.g., depression, anxiety, ADHD), and beyond, solving the problem of fragmented healthcare data by integrating it into actionable AI insights. Its dual revenue model—diagnostics labs and data licensing—powers growth, with ~95% of top 20 pharma companies as clients, partnerships with over 7,000 physicians, and support for nearly 1,500 research projects in a decade.[1][2]
Founded in 2015, Tempus emerged from visionary leadership, including CEO Eric Lefkofsky, who pivoted from prior ventures to address gaps in cancer care through data and AI. The idea stemmed from personal experience with cancer, leading to a platform that sequences tumor samples and applies AI for customized diagnoses—beyond mere sequencing, as a comprehensive data company.[1][2]
Early traction came via partnerships with academic institutions like Vanderbilt University Medical Center, where collaborations since 2018 enabled state-of-the-art testing and research addressing unmet cancer needs. Over ten years, Tempus evolved from oncology focus to multimodal data across diseases, building the world's largest clinical and molecular data library while amassing hundreds of research partners.[2][5]
Tempus stands out in precision medicine through integrated AI tools and a unique data moat:
Tempus rides the AI-in-healthcare wave, capitalizing on exploding multimodal data (clinical, genomic, imaging) amid rising precision medicine demand. Timing aligns with FDA clearances (e.g., ECG-Low EF software), generative AI adoption, and biopharma's need for real-world evidence in drug development—fueled by post-pandemic data silos and cost pressures.[4][5]
Market forces favor Tempus: healthcare's complexity burdens physicians, while biopharma seeks faster trials; its EHR integrations and 95% pharma penetration create a flywheel of data growth. Tempus influences the ecosystem by setting standards in AI diagnostics, accelerating discoveries (e.g., tumor heterogeneity insights), and bridging clinical care with R&D, positioning it centrally in global precision medicine.[1][2][6]
Tempus is primed for expansion with its data moat and AI tools like Tempus One scaling across diseases and EHRs. Next steps include deeper biopharma integrations for drug screening (e.g., organoids, imaging) and pathology via Paige, potentially capturing more of the $100B+ precision medicine market.[1][5][6]
Shaping trends—generative AI regulation, multimodal data standards, and value-based care—will amplify its edge, evolving Tempus from oncology pioneer to ubiquitous precision medicine OS. As it layers richer insights atop its dataset, Tempus will redefine how every patient benefits from collective health data, solidifying its lead in AI-driven care.[2][4]
